Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13492160 | 0.85 | MEN1 (0.45) | STK17BMEN1KMT2AIKBKBPIM1 | |
| SCHEMBL3219680 | 0.83 | BACE1 (0.44) | PIM1PIM2ALOX5HSD17B3 | |
| SCHEMBL3214270 | 0.80 | PLCG2 (0.47) | MEN1KMT2AALOX5LMNAHSD17B3 | |
| SCHEMBL4797164 | 0.80 | PLCG2 (0.47) | MEN1KMT2AALOX5LMNAHSD17B3 | |
| SCHEMBL2164772 | 0.79 | KDM4E (0.49) | STK17BMEN1KMT2ALMNATDP1 | |
| SCHEMBL2164776 | 0.79 | KDM4E (0.49) | STK17BMEN1KMT2ALMNATDP1 | |
| SCHEMBL2164768 | 0.79 | KDM4E (0.49) | STK17BMEN1KMT2ALMNATDP1 | |
| SCHEMBL3204969 | 0.79 | PIM1 (0.45) | PIM1PIM2ALOX5LMNA | |
| SCHEMBL1471995 | 0.76 | MEN1 (0.38) | MEN1KMT2ALMNAGAARAB9A | |
| SCHEMBL4801001 | 0.75 | PIM1 (0.38) | PIM1PIM2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| WO-2008040097-A1 | FURANONE COMPOUNDS AND LACTAM ANALOGUES THEREOF | BIOSIGNAL LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | FDPS, CYP2C19, MRPL21 | STK17B 1072/4885MEN1 559/4885KMT2A 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.